- Company
- Will 'Bylvay' be listed in the second half the year?
- by Eo, Yun-Ho Sep 18, 2025 06:04am
- Attention has been drawn to whether Bylvay, the first drug in the Concurrent Approval-Evaluation-Negotiation Pilot Program, will be approved for the reimbursement listing. Ipsen Korea is currently in negotiations with the National Health Insurance Service (NHIS) over the drug price for Bylvay (odevixibat), a treatment for pruritus in pati
- Company
- Rewriting the Medical Field with AI: KHF 2025
- by Hwang, byoung woo Sep 18, 2025 06:03am
- “Artificial intelligence (AI) technology is no longer just being applied to clinical settings; it is reshaping daily life.” Korea’s largest healthcare exhibition, the Korea-Hospital and Health Tech Fair (KHF2025), kicked off on the 17th at COEX in Seoul for three days. Experts and stakeholders at the venue remarked that the medica
- Company
- Alteogen secures EU authorization for Eylea biosimilar
- by Cha, Jihyun Sep 18, 2025 06:03am
- [Bio platform company Alteogen (CEO Soon-jae Park) announced on the 17th that it has obtained marketing authorization from the European Commission (EC) for ‘Eyluxvi (project name ALT-L9),’ an Eylea biosimilar it had jointly developed with Alteogen Biologics. Eyluxvi is Alteogen’s second biosimilar product to receive approval, following
- Company
- Samjin Pharm and Sanofi collide in the influenza vaccine mkt
- by Hwang, byoung woo Sep 17, 2025 06:12am
- With the influenza (flu) vaccination season approaching, competition in the vaccine market for adults aged 65 and over is anticipated. The government has switched the National Immunization Program (NIP) vaccine to a three-valent vaccine and lowered the procurement price. The introduction of the four-valent vaccine in the non-reimbursed medic
- Company
- Jemperli nears final hurdle for reimb in endometrial cancer
- by Eo, Yun-Ho Sep 17, 2025 06:11am
- The immunotherapy Jemperli is on the verge of securing expanded reimbursement coverage for endometrial cancer in Korea. According to industry sources, GSK Korea has recently finalized drug price negotiations with the National Health Insurance Service (NHIS) for the PD-1 inhibitor Jemperli (dostarlimab). The only step remaining is review
- Company
- Vivozon "Joint sales of Unafra with Daiichi Sankyo"
- by Kim, Jin-Gu Sep 17, 2025 06:10am
- Vivozon has chosen Daiichi Sankyo Korea as its co-promotion partner for Unafra Inj (opiranserin). The pharmaceutical industry points to two key reasons for this partnership: a synergy in sales and marketing for postoperative patient care, and the potential for Daiichi Sankyo Korea to play a positive role in Unafra's global market entry. s
- Company
- Did companies pre-stock inventories in the U.S.?
- by Kim, Jin-Gu Sep 17, 2025 06:10am
- The surge in Korean pharmaceutical exports to the United States&8212;driven by concerns over possible tariffs&8212;returned to normal levels within 2 months. Industry observers suggest that companies may have frontloaded shipments to secure inventories in the U.S. market. While exports have declined, some note that since tariff risks remain
- Company
- "PSA test determines prostate cancer survival rate"
- by Son, Hyung Min Sep 17, 2025 06:09am
- There is a growing need to introduce prostate-specific antigen (PSA) test for the early diagnosis of prostate cancer. On September 16, the Korean Urological Oncology Society held a press conference at the Press Center, highlighting current updates on prostate cancer and emphasizing the importance of early diagnosis through PSA testing.
- Company
- Will the new GVHD drug Rezurock be reimbursed in 2H?
- by Eo, Yun-Ho Sep 16, 2025 06:10am
- Attention is growing over whether the graft-versus-host disease (GVHD) treatment Rezurock will be included in the national health insurance reimbursement list in the second half of this year. Sanofi Korea’s ROCK2 inhibitor Rezurock (belumosudil) recently passed the Health Insurance Review and Assessment Service (HIRA)’s Drug Reimburseme
- Company
- Sanofi-MTPK sign exclusive sales agreement for Aubagio
- by Son, Hyung Min Sep 16, 2025 06:09am
- Mitsubishi Tanabe Pharma Korea (CEO Wonkyu Lee, MTPK) announced that it has entered into an exclusive domestic promotion and distribution agreement with the global biopharmaceutical company Sanofi Korea (General Manager Kyung Eun Bae), for the multiple sclerosis (MS) treatment Aubagio. The agreement officially took effect on September 1
